12,123 followers
RT @FrontOncology: New research: Cost-effectiveness analysis of toripalimab for metastatic or recurrent triple-negative breast cancer: Back…
RT @FrontOncology: New research: Cost-effectiveness analysis of toripalimab for metastatic or recurrent triple-negative breast cancer: Back…
New research: Cost-effectiveness analysis of toripalimab for metastatic or recurrent triple-negative breast cancer: Background Toliparibizumab in combination with nab-paclitaxel (T+N) has excellent efficacy inmetastatic or recurrent… https://t.co/KkmTtu64